{"id":83620,"date":"2022-06-09T00:00:00","date_gmt":"2022-06-09T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2022\/06\/09\/adt-pelvic-lymph-node-radiation-improves-prostate-cancer-outcomes\/"},"modified":"2022-06-13T17:25:21","modified_gmt":"2022-06-13T17:25:21","slug":"adt-pelvic-lymph-node-radiation-improves-prostate-cancer-outcomes","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2022\/06\/09\/adt-pelvic-lymph-node-radiation-improves-prostate-cancer-outcomes\/","title":{"rendered":"ADT + Pelvic Lymph Node Radiation Improves Prostate Cancer Outcomes"},"content":{"rendered":"<h3>\n<p>Five-year freedom from progression rate higher for those receiving short-term ADT and PLNRT in addition to salvage PBRT<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>THURSDAY, June 9, 2022 (HealthDay News) &#8212; The addition of androgen deprivation therapy (ADT) and pelvic lymph node radiotherapy (PLNRT) to prostate bed radiotherapy (PBRT) prolongs freedom from progression of prostate cancer following prostatectomy, according to a study published in the May 14 issue of <em>The Lancet<\/em>.<\/p>\n<p>Alan Pollack, M.D., from the University of Miami Miller School of Medicine, and colleagues conducted an international randomized trial involving patients with a persistently detectable or an initially undetectable and rising prostate-specific antigen of 0.1 to 2.0 ng\/mL after prostatectomy for adenocarcinoma of the prostate. A total of 1,792 patients were enrolled and randomly assigned to PBRT alone (group 1), PBRT plus short-term ADT (group 2), or PLNRT plus PBRT and short-term ADT (group 3; 592, 602, and 598 patients, respectively). The evaluable patient population included 1,716 patients.<\/p>\n<p>The researchers found that at the interim analysis, when group 1 was compared to group 3, the Haybittle-Peto boundary for five-year freedom from progression was exceeded (difference, 17.9 percent). Comparing groups 2 and 3, the difference did not exceed the boundary. At a median follow-up of 8.2 years, which was beyond the interim analysis, the five-year freedom from progression rates were 70.9, 81.3, and 87.4 percent in groups 1, 2, and 3, respectively. Freedom from progression was superior in group 3 versus groups 1 and 2 per protocol criteria.<\/p>\n<p>&#8220;Extension of the standard postprostatectomy salvage prostate bed radiotherapy fields to include the pelvic lymph nodes, when used in combination with short-term ADT, was found to result in the greatest impact on outcomes,&#8221; the authors write.<\/p>\n<p>Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n<p><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)01790-6\/fulltext\" target=\"_blank\" rel=\"noopener\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2022 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Five-year freedom from progression rate higher for those receiving short-term ADT and PLNRT in addition to salvage PBRT<\/p>\n","protected":false},"author":6,"featured_media":83880,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-83620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/83620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=83620"}],"version-history":[{"count":1,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/83620\/revisions"}],"predecessor-version":[{"id":83784,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/83620\/revisions\/83784"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/83880"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=83620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=83620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=83620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}